Acute Kidney Injury (AKI)- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s ‘Acute Kidney Injury (AKI) -Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Kidney Injury (AKI) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Kidney Injury (AKI) market size from 2017 to 2030. The report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Acute Kidney Injury (AKI) Disease Understanding and Treatment Algorithm
Acute Kidney Injury (AKI) Overview

AKI is characterized by a rapid fall in glomerular filtration rate, clinically manifest as an abrupt and sustained rise in urea and creatinine. Life threatening consequences include volume overload, hyperkalaemia, and metabolic acidosis. As per the American Kidney Foundation organization, AKI was formerly called Acute Kidney Injury. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes. Acute Kidney Injury is classified into three different phases including prerenal, postrenal and intrinsic renal. Pre-renal ARI is characterized by inadequate blood circulation to the kidneys, which leaves them to clean the body properly. Post-renal is characterized by acute obstruction to urinary flow which increases intratubular pressure and decreases GFR. Intrinsic AKI is the third type, which shows direct damage to kidneys by inflammation, toxins, drugs, and infections. The risk factors associated with AKI include age, exposure to nephrotoxins, family history, race and ethnicity, gender and others.

The DelveInsight Acute Kidney Injury market report gives the thorough understanding of the AKI by including details such as disease introduction, signs and symptoms, types of AKI, risk factors, causes, pathophysiology, stages of classification, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for AKI in the US, Europe, and Japan.

Acute Kidney Injury (AKI) Diagnosis
The diagnosis of AKI is traditionally based on a rise in serum creatinine and/or fall in urine output. The definition has evolved from the Risk, Injury, Failure, Loss, End-stage (RIFLE) criteria in 2004 to the AKI Network (AKIN) classification in 2007. In 2012, both were merged resulting in the Kidney Disease Improving Global Outcomes (KDIGO) classification. Accordingly, AKI is diagnosed if serum creatinine increases by 0.3 mg/dl (26.5 μmol/l) or more in 48 h or rises to at least 1.5-fold from baseline within 7 days. AKI stages are defined by the maximum change of either serum creatinine or urine output. The importance of both criteria was confirmed in a recent study in >32,000 critically ill patients which showed that short- and long-term risk of death or renal replacement therapy (RRT) were greatest when patients met both criteria for AKI and when these abnormalities persisted for longer than 3 days.

For diagnosing the disease, a patient history and physical examination are very crucial. The history should identify the use of nephrotoxic medications or systemic illnesses that might cause poor renal perfusion or directly impair renal function. Physical examination should assess intravascular volume status and any skin rashes indicative of systemic illness. The initial laboratory evaluation should include urinalysis, complete blood count, and measurement of serum creatinine level and fractional excretion of sodium. There are some tests which are generally used to diagnose the disease.

Acute Kidney Injury (AKI) Treatment
Management and treatment landscape of acute kidney injury involves fluid resuscitation, avoidance of nephrotoxic medications and contrast media exposure, and correction of electrolyte imbalances. Renal replacement therapy (dialysis) is indicated for refractory hyperkalemia; volume overload; intractable acidosis; uremic encephalopathy, pericarditis, or pleuritis; and removal of certain toxins. Recognition of risk factors (e.g., older age, sepsis, hypovolemia/shock, cardiac surgery, infusion of contrast agents, diabetes mellitus, preexisting chronic kidney disease, cardiac failure, liver failure) is important. Team-based approaches for prevention, early diagnosis, and aggressive management are critical for improving outcomes.

Supportive therapies (e.g., antibiotics, maintenance of adequate nutrition, mechanical ventilation, glycemic control, anemia management) should be pursued based on standard management practices. In patients with rapidly progressive glomerulonephritis, treatment with pulse steroids, cytotoxic therapy, or a combination may be considered, often after confirmation of the diagnosis by kidney biopsy

It covers the details of conventional and current medical therapies available in the AKI market for the treatment of the various types of AKI. It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight’s Acute Kidney Injury (AKI) market report gives a thorough understanding of Acute Kidney Injury (AKI) by including details such as disease introduction, causes, risk factors, pathogenesis, and diagnosis.

Acute Kidney Injury (AKI) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Acute Kidney Injury, Discharge Diagnosed Cases of Acute Kidney Injury, Stage-Wise Discharged Diagnosed Cases of Acute Kidney Injury, Risk Factor Associated Acute Kidney Injury Cases and Renal Transplantation Associated Delayed Graft Function scenario of Acute Kidney Injury (AKI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings
This section provides glimpse of the Acute Kidney Injury (AKI) epidemiology in the 7MM.
• The total incident population of Acute Kidney Injury in the seven major markets was found to be 1,525,519 in 2017. In the United States the incident population of Acute Kidney Injury was 895,078 in 2017, which is expected to increase in the forecast period (2020–2030).
• DelveInsight also estimates higher Diagnosed Discharge Cases of AKI in the United States with 532,830 diagnosed discharge cases found in 2017.
• According to KIDGO staging; stage II AKI corresponds to the relatively higher diagnosed discharge population with 223,789 cases in 2017 in the United States.

Country Wise- Acute Kidney Injury (AKI) Epidemiology
The epidemiology segment also provides the Acute Kidney Injury (AKI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acute Kidney Injury (AKI) Drug Chapters
The drug chapter segment of the AKI report encloses the detailed analysis of mid and late stage pipeline drugs. It also helps to understand the AKI clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Acute Kidney Injury (AKI) Emerging Drugs
EA-230: Exponential Biotherapies

EA-230 is being developed by Exponential Biotherapies, is an intravenously administered chemically synthesized linear peptide, a derivative of the human pregnancy hormone used for immunomodulation. During the preclinical studies, the drug has shown anti-inflammatory properties and protects against organ failure in several animal models of sepsis or systemic inflammation which lead to acute kidney injury. Most notably, EA-230 has shown marked protective effects in the kidney during abdominal sepsis in animals. As EA-230 attenuates the proinflammatory response in neutrophils and monocytes ex vivo, and neutrophil influx in tissues during systemic inflammation in vivo is abrogated, EA-230 acts by protecting the host against the detrimental effects of neutrophils during acute systemic inflammatory diseases, thereby preventing organ damage, especially in the kidney. EA-230 is under development by Exponential Biotherapies in collaboration with Radboud University.

Product detail in the report…
bRESCAP: Alloksys

RESCAP (Rescuing Alkaline Phosphatase), is an endogenous enzyme based on Alkaline Phosphatase (AP) a naturally occurring protein present in the body. It works as prophylactic and therapeutic anti-inflammatory protein that prevents ischemic injury by neutralizing and detoxifying inflammatory triggers that may derail the immune system. In acute settings, RESCAP triggers enhanced endogenous production of AP by the body, thereby boosting innate defense systems. bRESCAP is the type of RESCAP based on calf intestine from BSE free countries. It has a fast onset of action, a high dosing efficacy and a short residence time in the body (half-life of a few minutes), which makes the drug ideal for acute clinical disorder treatments.

ANG-3777 (BB3): Angion Biomedica
ANG-3777 (also known as BB3 and refanalin) is a small molecule hepatocyte growth factor/scatter factor (HGF/SF) being developed by Angion Biomedica. Its development is grounded in decades of research investigating the role of the HGF/c-Met pathway in organ repair. When an organ is injured, HGF expression peaks around 2 h but c-Met receptor expression peaks around 24–36 h, creating a mismatch between HGF and c-Met potentially resulting in suboptimal rates of organ self-repair. ANG-3777 is designed to address this challenging mismatch, supplementing endogenous HGF during peak c-MET receptor expression.

Product detail in the report…
Teprasiran (QPI-1002): Quark Pharmaceuticals

Teprasiran (QPI-1002) is a nuclease-resistant, synthetic double-stranded RNA oligonucleotide designed to temporarily inhibit the expression of the proapoptotic gene p53, via activation of the RNA interference (RNAi) pathway being developed by Quark Pharmaceuticals. Its development is based on the proprietary concept for temporary and reversible inhibition of p53 for therapeutic purposes. P53 is a stress-response gene activated by DNA damage, hypoxia, oxidative stress, and other conditions, leading to the induction of cell cycle arrest, cell senescence or apoptosis.

Product detail in the report…
ASP1128: Astellas Pharma

ASP1128 by Astellas Pharma is also known as MA-0217, is an investigational compound that is a potent and highly selective PPARδ modulator. ASP1128 has the potential to have protective effects on kidney cells that are under cellular stress following CABG/V surgery by promoting fatty acid oxidation in the mitochondria. Further, ASP1128 may have the potential to reduce systemic and local inflammatory responses and oxidative stress.

Product detail in the report…
Acute Kidney Injury (AKI) Market Outlook

Acute kidney injury (AKI) or acute renal failure (AKI) is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. The disease generally occurs as a complication of another serious disease and is more common in the geriatric population that suffers from various other diseases. The global burden of acute kidney injury has increased over the years. Among the 7 major markets, the United States has reported having maximum incident cases of AKI. Though the incident of AKI is high across the US, but the condition is often undiagnosed, ultimately leading to lower treatable pool (when compared to the total incident population of the disease) that contributes to the market size of AKI.

Currently there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury in the United States is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

The AKI market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted AKI market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of AKI market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, AKI 7MM market is expected to change in the study period 2017–2030.

Key Findings
This section includes a glimpse of the Acute Kidney Injury (AKI) 7MM market.
• There is no cure of AKI and the current treatment is aimed to manage the underlying cause and prognosis of AKI.
• Conventional therapies such as drugs to manage blood pressure, fluid overload and cardiac output, to stabilize hemodynamic and oxygenation parameters, glycemic control, nutritional support to reduce the severity of AKI are frequently used in manageable cases of AKI whereas in critically ill patients RRT therapies are recommended.
• The market size of Acute Kidney Injury (AKI) in the seven major markets was USD 4,082.95 million 2017 for the study period (2017–2030).
• The United States accounts for the largest market size of AKI in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan

The United States Market Outlook
This section provides the total Acute Kidney Injury (AKI) market size and market size by therapies in the United States.
EU-5 Market Outlook
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Acute Kidney Injury (AKI) market size and market size by therapies in Japan are provided.

Acute Kidney Injury (AKI) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017–2030. The analysis covers Acute Kidney Injury (AKI) market uptake by drugs and patient uptake by therapies.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Kidney Injury (AKI) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Acute Kidney Injury (AKI) emerging therapies.

Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Acute Kidney Injury (AKI) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Acute Kidney Injury (AKI), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Acute Kidney Injury (AKI) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute Kidney Injury (AKI) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Acute Kidney Injury (AKI) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Kidney Injury (AKI) market.

Report Highlights
• In the coming years, Acute Kidney Injury (AKI) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Kidney Injury (AKI) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players such as Exponential Biotherapies, Alloksys, Angion Biomedica, Quark Pharmaceuticals Astellas Pharma and others are involved in developing therapies for Acute Kidney Injury (AKI). Launch of emerging therapies such as ANG-3777 (BB3) by Angion Biomedica will significantly impact the Acute Kidney Injury (AKI) market due to the promising clinical trial results. The 28-patient study showed ANG-3777 improved kidney function, based on patients’ estimated glomerular filtration rate (eGFR), a key renal function metric. The drug also boosted urine output, caused no adverse events and may have reduced transplant failures. On the other hand, another major key player Quark Pharmaceuticals is a leader in the discovery and development of novel RNAi-based therapeutics for meeting unmet medical needs in AKI.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acute Kidney Injury (AKI) Report Insights
• Patient Population
• Therapeutic Approaches
• Acute Kidney Injury (AKI) Pipeline Analysis
• Acute Kidney Injury (AKI) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Acute Kidney Injury (AKI) Report Key Strengths
• Eleven Years Forecast
• 7MM Coverage
• Acute Kidney Injury (AKI) Epidemiology Segmentation (The segmentation consists of wider landscape covering different scenarios for developing the AKI model)
• The report covers Stage-Wise Discharge Diagnosed Cases of Acute Kidney Injury, which includes stages of AKI such as Stage I, Stage II and Stage III. Out of all the stages, Stage II showed the highest diagnosed discharge cases of AKI.
• The report also include Risk Factor Associated Acute Kidney Injury Cases, wherein several risk factors such as Coronary artery disease, Chronic kidney disease, Chronic lung disease, Sepsis, Cardiac surgery, etc are throroughly studied.
• An important segment of the report, i.e., Renal Transplantation Associated Delayed Graft Function provides scenario of Delayed Graft Function cases who undergo Renal Transplantation.

• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Acute Kidney Injury (AKI) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions
Market Insights:
• What was the Acute Kidney Injury (AKI) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Acute Kidney Injury (AKI) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Kidney Injury (AKI) market size during the forecast period (2020–2030)?
• At what CAGR, the Acute Kidney Injury (AKI) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the Acute Kidney Injury (AKI) market outlook across the 7MM during the forecast period (2020–2030)?
• What would be the Acute Kidney Injury (AKI) market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of Acute Kidney Injury (AKI)?
• What is the historical Acute Kidney Injury (AKI) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Acute Kidney Injury (AKI) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Kidney Injury (AKI)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Acute Kidney Injury (AKI) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of Acute Kidney Injury (AKI) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Acute Kidney Injury (AKI) in the US and Europe?
• What are the Acute Kidney Injury (AKI) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Acute Kidney Injury (AKI)?
• How many therapies are developed by each company for the treatment of Acute Kidney Injury (AKI)?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Acute Kidney Injury (AKI)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Kidney Injury (AKI) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Kidney Injury (AKI) and their status?
• What are the key designations that have been granted for the emerging therapies for Acute Kidney Injury (AKI)?
• What are the 7MM historical and forecasted market of Acute Kidney Injury (AKI)?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Acute Kidney Injury (AKI).
To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury (AKI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury (AKI) market.
To understand the future market competition in the Acute Kidney Injury (AKI) market.


1. Key Insights
2. The Report contains
3. Acute Kidney Injury Market (AKI): Overview at a Glance
3.1. Market Share Distribution of AKI in 2017
3.2. Market Share Distribution of AKI in 2030
4. Acute Kidney Injury (AKI): Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Types of Acute Kidney Injury
4.4. Stages Classification
4.5. Risk Factors
4.6. Etiology
4.7. Pathophysiology
4.8. Biomarkers
4.9. Diagnosis
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Incident Patient Population of AKI
5.3. 7MM Total Discharge Diagnosed Population of AKI
6. United States
6.1. Assumptions and Rationale
6.2. Acute Kidney Injury Incident Cases in the US
6.3. Acute Kidney Injury Discharge Diagnosed Cases in the US
6.4. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in the US
6.5. Acute Kidney Injury Risk Factor Associated Cases in the US
6.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the US
7. EU5
7.1. Assumptions and Rationale
7.2. Germany
7.2.1. Acute Kidney Injury Incident Cases in Germany
7.2.2. Acute Kidney Injury Discharge Diagnosed Cases in Germany
7.2.3. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in Germany
7.2.4. Acute Kidney Injury Risk Factor Associated Cases in Germany
7.2.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Germany
7.3. France
7.3.1. Acute Kidney Injury Incident Cases in France
7.3.2. Acute Kidney Injury Discharge Diagnosed Cases in France
7.3.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in France
7.3.4. Acute Kidney Injury Risk Factor Associated Cases in France
7.3.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in France
7.4. Italy
7.4.1. Acute Kidney Injury Incident Cases in Italy
7.4.2. Acute Kidney Injury Discharge Diagnosed Cases in Italy
7.4.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Italy
7.4.4. Acute Kidney Injury Risk Factor Associated Cases in Italy
7.4.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Italy
7.5. Spain
7.5.1. Acute Kidney Injury Incident Cases in Spain
7.5.2. Acute Kidney Injury Discharge Diagnosed Cases in Spain
7.5.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Spain
7.5.4. Acute Kidney Injury Risk Factor Associated Cases in Spain
7.5.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Spain
7.6. United Kingdom
7.6.1. Acute Kidney Injury Incident Cases in the UK
7.6.2. Acute Kidney Injury Discharge Diagnosed Incident Cases in the UK
7.6.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in the UK
7.6.4. Acute Kidney Injury Risk Factor Associated Cases in the UK
7.6.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the UK
8. Japan
8.1.1. Assumptions and Rationale
8.1.2. Acute Kidney Injury Incident Cases in Japan
8.1.3. Acute Kidney Injury Discharge Diagnosed Cases Japan
8.1.4. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Japan
8.1.5. Acute Kidney Injury Risk Factor Associated Cases in Japan
8.1.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Japan
9. Treatment and Prevention
10. Unmet Needs
11. Emerging Therapies
11.1. Key cross competition- Emerging Therapies
12. Emerging Therapies
12.1. EA-230: Exponential Biotherapies
12.1.1. Clinical Development
12.1.2. Clinical Trials Information
12.1.3. Safety and Efficacy
12.1.4. Product Profile
12.2. bRESCAP: Alloksys
12.2.1. Other Developmental Activities
12.2.2. Clinical Trials Information
12.2.3. Safety and Efficacy
12.2.4. Product Profile
12.3. ANG-3777 (BB3) : Angion Biomedica
12.3.1. Other Developmental Activities
12.3.2. Clinical Trials Information
12.3.3. Safety and Efficacy
12.3.4. Product Profile
12.4. QPI-1002: Quark Pharmaceuticals
12.4.1. Other Developmental Activities
12.4.2. Clinical Development
12.4.3. Clinical Trial Information
12.4.4. Safety and Efficacy
12.4.5. Advantages and Disadvantages
12.4.6. Product Profile
12.5. recAP: AM Pharma
12.5.1. Other Developmental Activities
12.5.2. Clinical Development
12.5.3. Clinical Trial Information
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. Reltecimod: AtoxBio
12.6.1. Other Developmental Activities
12.6.2. Clinical Development
12.6.3. Clinical Trial Information
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.7. ASP1128: Astellas Pharma
12.7.1. Other Developmental Activities
12.7.2. Clinical Development
12.7.3. Clinical Trial Information
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.8. Ruconest (Conestat alfa): Pharming Technologies
12.8.1. Other Developmental Activities
12.8.2. Clinical Development
12.8.3. Clinical Trial Information
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. MB-102: MediBeacon
12.9.1. Other Developmental Activities
12.9.2. Clinical Development
12.9.3. Clinical Trial Information
12.9.4. Safety and Efficacy
12.9.5. Product Profile
12.10. Levosimendan (Simdax): Orion Pharma
12.10.1. Clinical Development
12.10.2. Clinical Trial Information
12.10.3. Safety and Efficacy
12.10.4. Product Profile
13. Acute Kidney Injury: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Size of AKI in 7MM
14. United States Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of AKI
14.1.2. Market Size by Therapies
15. EU-5 Countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of AKI
15.1.2. Market Size by Therapies
15.2. France Market Size
15.2.1. Total Market size of AKI
15.2.2. Market Size by Therapies
15.3. Italy Market Size
15.3.1. Total Market size of AKI
15.3.2. Market Size by Therapies
15.4. Spain Market Size
15.4.1. Total Market size of AKI
15.4.2. Market Size by Therapies
15.5. United Kingdom Market Size
15.5.1. Total Market size of AKI
15.5.2. Market Size by Therapies
16. Japan: Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of AKI
16.1.2. Market Size by Therapies
17. Trends in the Cost of Therapies in Acute Kidney Injury
18. Market Access and Reimbursement Scenario of Acute Kidney Injury
18.1. Centers of Medicare and Medicaid Services (US)
18.2. American Kidney Fund (AKF)
18.3. Reimbursement and Cost of Acute Kidney Injury in Europe
18.3.1. United Kingdom (England)
18.3.2. France
18.3.3. Germany
18.3.4. Italy
19. Market Drivers
20. Market Barriers
21. Case Reports
21.1. A simple real-time model for predicting acute kidney injury in hospitalized patients in the US: A descriptive modeling study
21.2. Acute kidney injury in the UK: a replication cohort study of the variation across three regional populations
21.3. Exercise-Induced Acute Kidney Injury in a Police Officer with Hereditary Renal Hypouricemia (Japan)
22. SWOT Analysis for Acute Kidney Injury
23. Appendix
23.1. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
Table 1 Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification
Table 2 KDIGO Criteria
Table 3 Causes of AKI: Exposures and Susceptibilities for non-specific AKI
Table 4 Biomarkers of AKI
Table 5 RIFLE Criteria for AKI
Table 6 AKIN Criteria for AKI
Table 7 KDIGO Criteria for AKI
Table 8 Total Incident Population of AKI in the 7MM (2017–2030)
Table 9 Total Discharge Diagnosed Population of AKI in the 7MM (2017–2030)
Table 10 AKI Incident Cases in the US (2017–2030)
Table 11 AKI Discharge Diagnosed Cases in the US (2017–2030)
Table 12 AKI Stage-Wise Discharged Diagnosed Cases in the US (2017–2030)
Table 13 AKI Risk Factor Associated Cases in the US (2017–2030)
Table 14 AKI Renal Transplantation Associated Delayed Graft Function Cases in the US (2017–2030)
Table 15 AKI Incident Cases in Germany (2017–2030)
Table 16 AKI Discharge Diagnosed Cases in Germany (2017–2030)
Table 17 AKI Stage-Wise Incident Cases in Germany (2017–2030)
Table 18 AKI Risk Factor Associated Cases in Germany (2017–2030)
Table 19 AKI Renal Transplantation Associated Delayed Graft Function Cases in Germany (2017–2030)
Table 20 AKI Incident Cases in France (2017–2030)
Table 21 AKI Discharge Diagnosed Cases in France (2017–2030)
Table 22 AKI Stage-Wise Discharge Diagnosed Cases in France (2017–2030)
Table 23 AKI Risk Factor Associated Cases in France (2017–2030)
Table 24 AKI Renal Transplantation Associated Delayed Graft Function Cases in France (2017–2030)
Table 25 AKI Incident Cases in Italy (2017–2030)
Table 26 AKI Discharge Diagnosed Cases in Italy (2017–2030)
Table 27 AKI Stage-Wise Discharge Diagnosed Cases in Italy (2017–2030)
Table 28 AKI Risk Factor Associated Cases in Italy (2017–2030)
Table 29 AKI Renal Transplantation Associated Delayed Graft Function Cases in Italy (2017–2030)
Table 30 AKI Incident Cases in Spain (2017–2030)
Table 31 AKI Discharge Diagnosed Cases in Spain (2017–2030)
Table 32 AKI Stage-Wise Discharge Diagnosed Cases in Spain (2017–2030)
Table 33 AKI Risk Factor Associated Cases in Spain (2017–2030)
Table 34 AKI Renal Transplantation Associated Delayed Graft Function Cases in Spain (2017–2030)
Table 35 AKI Incident Cases in the UK (2017–2030)
Table 36 AKI Discharge Diagnosed Cases in the UK (2017–2030)
Table 37 AKI Stage-Wise Discharge Diagnosed Cases in the UK (2017–2030)
Table 38 AKI Risk Factor Associated Cases in the UK (2017–2030)
Table 39 AKI Renal Transplantation Associated Delayed Graft Function Cases in the UK (2017–2030)
Table 40 AKI Incident Cases in Japan (2017–2030)
Table 41 AKI Discharge Diagnosed Cases in Japan (2017–2030)
Table 42 AKI Stage-Wise Discharge Diagnosed Cases in Japan (2017–2030)
Table 43 AKI Risk Factor Associated Cases in Japan (2017–2030)
Table 44 AKI Renal Transplantation Associated Delayed Graft Function Cases in Japan (2017–2030)
Table 45 AKI Renal Replacement Therapy (RRT) Modalities for AKI
Table 46 Key Cross – Emerging Therapies
Table 47 EA-230, Clinical Trials Description, 2020
Table 48 bRESCAP, Clinical Trial Description, 2020
Table 49 ANG-3777 (BB3), Clinical Trial Description, 2020
Table 50 QPI-1002, Clinical Trial Description, 2020
Table 51 recAP, Clinical Trial Description, 2020
Table 52 Reltecimod, Clinical Trial Description, 2020
Table 53 ASP1128, Clinical Trials Description, 2020
Table 54 Ruconest (Conestat alfa), Clinical Trials Description, 2020
Table 55 MB-102, Clinical Trials Description, 2020
Table 56 Levosimendan (Simdax), Clinical Trials Description, 2020
Table 57 7 Major Market Size of AKI in USD Million (2017–2030)
Table 58 Market Size of AKI in the US, USD Million (2017–2030)
Table 59 Market size of AKI by therapies in the US, in USD Million (2017–2030)
Table 60 Market Size of AKI in Germany, USD Million (2017–2030)
Table 61 Market size of AKI by therapies in Germany, in USD Million (2017–2030)
Table 62 Market Size of AKI in France, USD Million (2017–2030)
Table 63 Market size of AKI by therapies in France, in USD Million (2017–2030)
Table 64 Market Size of AKI in Italy, USD Million (2017–2030)
Table 65 Market size of AKI by therapies in Italy, in USD Million (2017–2030)
Table 66 Market Size of AKI in Spain, USD Million (2017–2030)
Table 67 Market size of AKI by therapies in Spain, in USD Million (2017–2030)
Table 68 Market Size of AKI in the UK, USD Million (2017–2030)
Table 69 Market size of AKI by therapies in the UK, in USD Million (2017–2030)
Table 70 Market Size of AKI in Japan, USD Million (2017–2030)
Table 71 Market size of AKI by therapies in Japan, in USD Million (2017–2030)
Table 72 Trends in the Cost of Therapies in Acute Kidney Injury
Figure 1 Types of Acute Kidney Injury
Figure 2 Risk factors associated with Acute Kidney Injury
Figure 3 Common Causes of AKI
Figure 4 Pathophysiology of AKI
Figure 5 Biomarkers of AKI
Figure 6 Total Incident Patient Population of AKI in the 7MM (2017–2030)
Figure 7 Total Discharge Diagnosed Population of AKI in the 7MM (2017–2030)
Figure 8 AKI Incident Cases in the US (2017–2030)
Figure 9 AKI Discharge Diagnosed Cases in the US (2017–2030)
Figure 10 AKI Stage-Wise Discharged Diagnosed Cases in the US (2017–2030)
Figure 11 AKI Risk Factor Associated Cases in the US (2017–2030)
Figure 12 AKI Renal Transplantation Associated Delayed Graft Function Cases in the US (2017–2030)
Figure 13 AKI Incident Cases in Germany (2017–2030)
Figure 14 AKI Discharge Diagnosed Cases in Germany (2017–2030)
Figure 15 AKI Stage-Wise Incident Cases in Germany (2017–2030)
Figure 16 AKI Risk Factor Associated Cases in Germany (2017–2030)
Figure 17 AKI Renal Transplantation Associated Delayed Graft Function Cases in Germany (2017–2030)
Figure 18 AKI Incident Cases in France (2017–2030)
Figure 19 AKI Discharge Diagnosed Cases in France (2017–2030)
Figure 20 AKI Stage-Wise Discharge Diagnosed Cases in France (2017–2030)
Figure 21 AKI Risk Factor Associated Cases in France (2017–2030)
Figure 22 AKI Renal Transplantation Associated Delayed Graft Function Cases in France (2017–2030)
Figure 23 AKI Incident Cases in Italy (2017–2030)
Figure 24 AKI Discharge Diagnosed Cases in Italy (2017–2030)
Figure 25 AKI Stage-Wise Discharge Diagnosed Cases in Italy (2017–2030)
Figure 26 AKI Risk Factor Associated Cases in Italy (2017–2030)
Figure 27 AKI Renal Transplantation Associated Delayed Graft Function Cases in Italy (2017–2030)
Figure 28 AKI Incident Cases in Spain (2017–2030)
Figure 29 AKI Discharge Diagnosed Cases in Spain 2017–2030)
Figure 30 AKI Stage-Wise Discharge Diagnosed Cases in Spain (2017–2030)
Figure 31 AKI Risk Factor Associated Cases in Spain (2017–2030)
Figure 32 AKI Renal Transplantation Associated Delayed Graft Function Cases in Spain (2017–2030)
Figure 33 AKI Incident Cases in the UK (2017–2030)
Figure 34 AKI Discharge Diagnosed Cases in the UK (2017–2030)
Figure 35 AKI Stage-Wise Discharge Diagnosed Cases the UK (2017–2030)
Figure 36 AKI Risk Factor Associated Cases in the UK (2017–2030)
Figure 37 AKI Renal Transplantation Associated Delayed Graft Function Cases in the UK (2017–2030)
Figure 38 AKI Incident Cases of in Japan (2017–2030)
Figure 39 AKI Discharge Diagnosed Incident Cases in Japan (2017–2030)
Figure 40 AKI Stage-Wise Discharge Diagnosed Cases in Japan (2017–2030)
Figure 41 AKI Risk Factor Associated Cases in Japan (2017–2030)
Figure 42 AKI Renal Transplantation Associated Delayed Graft Function Cases in Japan (2017–2030)
Figure 43 Global Mortality of AKI
Figure 44 Stage-based management of Acute Kidney Injury (AKI)
Figure 45 Unmet Needs for AKI
Figure 46 7 Major Market Size of AKI in USD Million (2017–2030)
Figure 47 Market Size of AKI in the US, USD Million (2017–2030)
Figure 48 Market size of AKI by therapies in the US, in USD Million (2017–2030)
Figure 49 Market Size of AKI in Germany, USD Million (2017–2030)
Figure 50 Market size of AKI by therapies in Germany, in USD Million (2017–2030)
Figure 51 Market Size of AKI in France, USD Million (2017–2030)
Figure 52 Market size of AKI by therapies in France, in USD Million (2017–2030)
Figure 53 Market Size of AKI in Italy, USD Million (2017–2030)
Figure 54 Market size of AKI by therapies in Italy, in USD Million (2017–2030)
Figure 55 Market Size of AKI in Spain, USD Million (2017–2030)
Figure 56 Market size of AKI by therapies in Spain, in USD Million (2017–2030)
Figure 57 Market Size of AKI in the UK, USD Million (2017–2030)
Figure 58 Market size of AKI by therapies in the UK, in USD Million (2017–2030)
Figure 59 Market Size of AKI in Japan, USD Million (2017–2030)
Figure 60 Market size of AKI by therapies in Japan, in USD Million (2017–2030)
Figure 61 Market Drivers
Figure 62 Market Barriers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook